 Citius Pharmaceuticals, Inc. Citius or the Company Nasdaq: CTXR, a specialty pharmaceutical company focused on developing and commercializing critical care drug products, announced today the closing of its previously announced underwritten public offering of 9,159,524 shares of common stock of the Company, including the exercise in full by the underwriter of the option to purchase an additional 1,194,720 shares of common stock, at a price to the public of 1.05 per share. 